Imagine trying to listen to a conversation in a room through a thick concrete wall; that is how the skull blocks brain signals for doctors. This project creates a special 'electric dye' that can be introduced to the brain to amplify those signals. It allows doctors to see brain activity with crystal clarity without having to drill holes in the patient's head.
Current high-resolution brain imaging requires drilling holes in the skull (trepanation), which is invasive and risky. Non-invasive scalp EEG exists but lacks the spatial accuracy needed for precise medical diagnostics.
A contrast-medium system consisting of a CMOS front-end architecture, digital-based amplifiers, and elongated magnetic nanorods for signal amplification.
If you are a medical device company dealing with the trade-off between invasive surgery and low-resolution scalp EEG — this project developed a contrast-medium concept that provides high-accuracy imaging without skull trepanation.
If you are a biotech firm dealing with the delivery of functional particles to the brain — this project developed elongated magnetic nanorods that generate spectral replicas of neural signals.
If you are a clinic dealing with the risks and recovery times of ECoG and StereoEEG implants — this project developed a non-invasive way to image the entire brain with the same accuracy as invasive methods.
Based on available project data, there is no specific pricing or unit cost mentioned for the contrast medium or the hardware.
The project has defined a compact CMOS front-end architecture and explored nanoparticle pathways, but industrial scaling data is not provided.
Based on available project data, specific patents or licensing terms are not listed, though the project is currently in the prototype and validation phase.
The project developed a digital-based amplifier and CMOS front-end to translate low-frequency neural activity into higher-frequency bands for external detection.
The project period runs from 2022-09-01 to 2026-08-31, suggesting it is still in the development phase.
The consortium consists of 5 partners across 4 countries (AT, CH, FR, IT). It is heavily academic, with 4 universities and only 1 SME, resulting in an industry ratio of 20%. This suggests the project is currently driven by fundamental research and early-stage technical validation rather than immediate commercialization.
Contact Politecnico di Torino regarding the CMOS front-end and nanoparticle prototypes.
Contact us to find licensing opportunities for the CEREBRO contrast-medium technology.
